Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis.

Autor:	Bestvina CM; Department of Medicine, University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, Illinois., Whisenant JG; Vanderbilt University Medical Center, Nashville, Tennessee., Torri V; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy., Cortellini A; Department of Surgery and Cancer, Imperial College London, London, United Kingdom., Wakelee H; Stanford Cancer Institute, Stanford University, Stanford, California., Peters S; Lausanne University Hospital, Lausanne University, Lausanne, Switzerland., Roca E; Thoracic Oncology-Lung Unit, Ospedale Pederzoli, Peschiera dG, Verona, Italy., De Toma A; Thoracic Oncology Unit, Medical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy., Hirsch FR; Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine Mount Sinai, New York, New York., Mamdani H; Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan., Halmos B; Division of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York., Arrieta O; Thoracic Oncology Unit, Instituto Nacional de Cancerologia (INCan), Mexico City, Mexico., Metivier AC; Department of Pneumology, Hopital Foch, Suresnes, France., Fidler MJ; Department of Hematology, Oncology, and Cell Therapy, Rush University Medical Center, Chicago, Illinois., Rogado J; Seccion de Oncologia Medica, Hospital Universitario Infanta Leonor, Madrid, Spain., Presley CJ; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Mascaux C; Service De Pneumologie, Hopitaux Universitaires De Strasbourg, Strasbourg, France.; Laboratory Streinth (Stress REsponse and INnovative THerapy against Cancer), Inserm UMR_S 1113, IRFAC, ITI InnoVec, Universite De Strasbourg, Strasbourg, France., Genova C; UOC Clinica di Oncologia Medica, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, Genoa, Italy.; Dipartimento di Medicina Interna e Specialita Mediche (DIMI), Universita degli Studi di Genova, Genoa, Italy., Blaquier JB; Thoracic Oncology Section, Centro de Educacion Medica e Investigaciones Clinicas (CEMIC), Buenos Aires, Argentina., Addeo A; University Hospital of Geneva, Geneva, Switzerland., Finocchiaro G; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy., Khan H; The Warren Alpert Medical School of Brown University, Providence, Rhode Island., Mazieres J; Toulouse University Hospital, Université Paul Sabatier, Toulouse, France., Morgillo F; Department of Precision Medicine, Medical Oncology and Haematology, Universita degli studi della Campania 'L. Vanvitelli,' Naples, Italy., Bar J; Institute of Oncology, Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel., Aujayeb A; Respiratory Department, Northumbria Healthcare NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom., Mountzios G; Fourth Department of Medical Oncology and Clinical Trials Unit Henry Dunant Hospital Center, Athens, Greece., Scotti V; Department of Oncology, Radiation Therapy Unit, Careggi University Hospital, Florence, Italy., Grosso F; Mesothelioma and Rare Cancer Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy., Geraedts E; Groene Hart Ziekenhuis, Gouda, The Netherlands., Zhumagaliyeva AN; Semey Medical University, Center for Nuclear Medicine and Oncology of Semey, Semey, Kazakhstan., Horn L; Vanderbilt University Medical Center, Nashville, Tennessee., Garassino MC; Department of Medicine, University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, Illinois., Baena J; Hospital Universitario 12 de Octubre, Madrid, Spain.
Jazyk:	angličtina
Zdroj:	JTO clinical and research reports [JTO Clin Res Rep] 2022 Aug; Vol. 3 (8), pp. 100335. Date of Electronic Publication: 2022 May 20.
DOI:	10.1016/j.jtocrr.2022.100335
Abstrakt:	Introduction: The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID-19 surges. Data from South Africa suggested a decrease in severity and mortality with the Omicron wave. Our objective was to assess mortality of patients with thoracic malignancies with the Omicron-predominant wave and evaluate efficacy of vaccination. Methods: A prospective, multicenter observational study was conducted. A total of 28 institutions contributed data from January 14, 2022, to February 4, 2022. Inclusion criteria were any thoracic cancer and a COVID-19 diagnosis on or after November 1, 2021. End points included mortality, hospitalization, symptomatic COVID-19 infection, asymptomatic COVID-19 infection, and delay in cancer therapy. Analysis was done through contingency tables and a multivariable logistic model. Results: We enrolled a total of 346 patients. Median age was 65 years, 52.3% were female, 74.2% were current or former smokers, 86% had NSCLC, 72% had stage IV at time of COVID-19 diagnosis, and 66% were receiving cancer therapy. Variant was unknown for 70%; for those known, Omicron represented 82%. Overall mortality was 3.2%. Using multivariate analysis, COVID-19 vaccination with booster compared with no vaccination had a protective effect on hospitalization or death (OR = 0.30, confidence interval: 0.15-0.57, p  = 0.0003), whereas vaccination without booster did not (OR = 0.64, confidence interval: 0.33-1.24, p  = 0.1864). Cancer care was delayed in 56.4% of the patients. Conclusions: TERAVOLT found reduced patient mortality with the most recent COVID-19 surge. COVID-19 vaccination with booster improved outcomes of hospitalization or death. Delays in cancer therapy remain an issue, which has the potential to worsen cancer-related mortality. (© 2022 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu